Document:

<Page>
                                                                     Exhibit 4.5

                           REGISTRATION RIGHTS AGREEMENT

                                  by and among

                                 Videotron Ltee

                                      and

                   The Guarantors listed on Schedule A hereto

                                      and

                         Banc of America Securities LLC
                         Citigroup Global Markets Inc.
                           Scotia Capital (USA) Inc.
                              Harris Nesbitt Corp.
                        RBC Capital Markets Corporation
                            TD Securities (USA) LLC
                            CIBC World Markets Corp.
                         Credit Suisse First Boston LLC
                           NBF Securities (USA) Corp.
                           HSBC Securities (USA) Inc.
                    Desjardins Securities International Inc.

                         Dated as of September 16, 2005
<Page>
                         REGISTRATION RIGHTS AGREEMENT

    This Registration Rights Agreement (this "Agreement") is made and entered
into as of September 16, 2005, by and among Videotron Ltee, a company
incorporated under the laws of the Province of Quebec (the "Company"), the
guarantors listed on Schedule A hereto (the "Guarantors") and Banc of America
Securities LLC, Citigroup Global Markets Inc., Scotia Capital (USA) Inc., Harris
Nesbitt Corp., RBC Capital Markets Corporation, TD Securities (USA) LLC, CIBC
World Markets Corp., Credit Suisse First Boston LLC, NBF Securities (USA) Corp.,
HSBC Securities (USA) Inc. and Desjardins Securities International Inc. (each an
"Initial Purchaser" and, collectively, the "Initial Purchasers"). Each of the
Initial Purchasers has agreed to purchase the Company's Initial Notes
(as defined below) pursuant to the Purchase Agreement (as defined below).

    This Agreement is made pursuant to the Purchase Agreement (as defined
below). In order to induce the Initial Purchasers to purchase the Initial Notes,
the Company and the Guarantors have agreed, for the benefit of each Initial
Purchaser and for the benefit of the holders from time to time of the Notes
(including each Initial Purchaser) to provide the registration rights set forth
in this Agreement. The execution and delivery of this Agreement is a condition
to the obligations of the Initial Purchasers set forth in Section 5(h) of the
Purchase Agreement, and capitalized terms not defined herein are used as defined
in the Purchase Agreement.

    The parties hereby agree as follows:

SECTION 1.  DEFINITIONS.  As used in this Agreement, the following capitalized
terms shall have the following meanings:

    ADVICE:  As defined in Section 6(c) hereof.

    BROKER-DEALER:  Any broker or dealer registered as such under the Exchange
Act.

    BUSINESS DAY:  Any day other than a Saturday, a Sunday or a legal holiday or
a day on which banking institutions or trust companies are authorized or
obligated by law to close in New York City.

    CLOSING DATE:  The date of this Agreement.

    COMMISSION:  The United States Securities and Exchange Commission.

    CONSUMMATE:  A registered Exchange Offer shall be deemed "Consummated" for
purposes of this Agreement when (i) the Exchange Offer Registration Statement
has been filed and declared effective by the Commission, (ii) such Registration
Statement was kept continuously effective and the Exchange Offer was kept open
for a period not less than the minimum period required pursuant to
Section 3(b) hereof and (iii) the Company has delivered to the Registrar under
the Indenture Exchange Notes in the same aggregate principal amount as the
aggregate principal amount of Initial Notes that were tendered by Holders
thereof pursuant to the Exchange Offer.

    CONTROLLING PERSON:  As defined in Section 8(a) hereof.

    EFFECTIVENESS TARGET DATE:  As defined in Section 5 hereof.

    EXCHANGE ACT:  The United States Securities Exchange Act of 1934, as
amended.

    EXCHANGE NOTES:  The 6 3/8% Senior Notes due December 15, 2015, of the same
series under the Indenture as the Initial Notes, including the Guarantees
attached thereto, to be issued to Holders in exchange for Transfer Restricted
Securities pursuant to this Agreement.

    EXCHANGE OFFER:  The registration under the Securities Act of the Exchange
Notes pursuant to a Registration Statement pursuant to which the Holders of all
outstanding Transfer Restricted Securities are offered the opportunity to
exchange all such outstanding Transfer Restricted Securities held by such
Holders for Exchange Notes in an aggregate principal amount equal to the
aggregate principal amount of the Transfer Restricted Securities tendered in
such exchange offer by such Holders.

    EXCHANGE OFFER REGISTRATION STATEMENT:  The Registration Statement relating
to the Exchange Offer, including the related Prospectus.

                                       2
<Page>
    FORM 20-F:  Form 20-F under the Exchange Act.

    HOLDER:  As defined in Section 2(b) hereof.

    INDEMNIFIED HOLDER:  As defined in Section 8(a) hereof.

    INDENTURE:  The Indenture, dated as of the Closing Date, among the Company,
the Guarantors and Wells Fargo Bank, National Association, as trustee
(the "Trustee"), pursuant to which the Notes are to be issued, as such Indenture
is amended or supplemented from time to time in accordance with the terms
thereof.

    INITIAL NOTES:  The 6 3/8% Senior Notes due December 15, 2015, of the same
series under the Indenture as the Exchange Notes, including the Guarantees
attached thereto, for so long as such securities constitute Transfer Restricted
Securities.

    INITIAL PLACEMENT:  The issuance and sale by the Company of the Initial
Notes to the Initial Purchasers pursuant to the Purchase Agreement.

    INTEREST PAYMENT DATE:  As defined in the Indenture and the Notes.

    NASD:  National Association of Securities Dealers, Inc.

    NOTES:  The Initial Notes and the Exchange Notes.

    PERSON:  An individual, partnership, corporation, trust or unincorporated
organization, or a government or agency or political subdivision thereof.

    PROSPECTUS:  The prospectus included in a Registration Statement, as amended
or supplemented by any prospectus supplement and by all other amendments
thereto, including post-effective amendments, and all material incorporated by
reference into such Prospectus.

    PURCHASE AGREEMENT:  The Purchase Agreement, dated as of September 9, 2005,
among the Company, the Guarantors and the Initial Purchasers.

    REGISTRATION DEFAULT:  As defined in Section 5 hereof.

    REGISTRATION STATEMENT:  Any registration statement of the Company and the
Guarantors relating to (a) an offering of Exchange Notes pursuant to an Exchange
Offer or (b) the registration for resale of Transfer Restricted Securities
pursuant to the Shelf Registration Statement, which is filed pursuant to the
provisions of this Agreement, in each case, including the Prospectus included
therein, all amendments and supplements thereto (including post-effective
amendments) and all exhibits and material incorporated by reference therein.

    REGULATION S-K:  Regulation S-K under the Securities Act.

    SECURITIES ACT:  The United States Securities Act of 1933, as amended.

    SHELF FILING DEADLINE:  As defined in Section 4(a) hereof.

    SHELF REGISTRATION STATEMENT:  As defined in Section 4(a) hereof.

    SPECIAL INTEREST:  As defined in Section 5 hereof.

    TRANSFER RESTRICTED SECURITIES:  Each Initial Note, until the earliest to
occur of (a) the date on which such Initial Note is exchanged in the Exchange
Offer and entitled to be resold to the public by the Holder thereof without
complying with the prospectus delivery requirements of the Securities Act,
(b) the date on which such Initial Note has been effectively registered under
the Securities Act and disposed of in accordance with a Shelf Registration
Statement and (c) the date on which such Initial Note is distributed to the
public pursuant to Rule 144 under the Securities Act or by a Broker-Dealer
pursuant to the "Plan of Distribution" contemplated by the Exchange Offer
Registration Statement (including delivery of the Prospectus contained therein).

                                       3
<Page>
    TRUST INDENTURE ACT:  The United States Trust Indenture Act of 1939
(15 U.S.C. Section 77aaa, et seq.) as in effect on the date of the Indenture.

    UNDERWRITTEN REGISTRATION OR UNDERWRITTEN OFFERING:  A registration in which
securities of the Company are sold to an underwriter for reoffering to the
public.

SECTION 2.  SECURITIES SUBJECT TO THIS AGREEMENT.

    (a) TRANSFER RESTRICTED SECURITIES.  The securities entitled to the benefits
of this Agreement are the Transfer Restricted Securities.

    (b) HOLDERS OF TRANSFER RESTRICTED SECURITIES.  A Person is deemed to be a
holder of Transfer Restricted Securities (each, a "Holder") whenever such Person
owns Transfer Restricted Securities.

SECTION 3.  REGISTERED EXCHANGE OFFER.

    (a) Unless the Exchange Offer shall not be permissible under applicable law
or Commission policy (after the procedures set forth in Section 6(a) below have
been complied with), the Company and the Guarantors shall (i) cause to be filed
with the Commission as soon as practicable after the Closing Date, but in no
event later than 45 days after the Closing Date (or if such 45th day is not a
Business Day, the next succeeding Business Day), a Registration Statement under
the Securities Act relating to the Exchange Notes and the Exchange Offer,
(ii) use their best efforts to cause such Registration Statement to become
effective at the earliest possible time, but in no event later than 120 days
after the Closing Date (or if such 120th day is not a Business Day, the next
succeeding Business Day), (iii) in connection with the foregoing, (A) file all
pre-effective amendments to such Registration Statement as may be necessary in
order to cause such Registration Statement to become effective, (B) file, if
applicable, a post-effective amendment to such Registration Statement pursuant
to Rule 430A under the Securities Act and (C) cause all necessary filings in
connection with the registration and qualification of the Exchange Notes to be
made under the Blue Sky laws of such jurisdictions as are necessary to permit
Consummation of the Exchange Offer and (iv) upon the effectiveness of such
Registration Statement, commence the Exchange Offer. The Exchange Offer
Registration Statement shall be on the appropriate form permitting registration
of (i) the offers of the Exchange Notes in exchange for the Transfer Restricted
Securities and (ii) the resales of Exchange Notes held by Broker-Dealers as
contemplated by Section 3(c) below.

    (b) The Company and the Guarantors shall cause the Exchange Offer
Registration Statement to be effective continuously and shall keep the Exchange
Offer open for a period of not less than the minimum period required under
applicable federal and state securities laws to Consummate the Exchange Offer;
PROVIDED, HOWEVER, that in no event shall such period be less than 30 days after
the date notice of the Exchange Offer is mailed to the Holders. The Company and
the Guarantors shall cause the Exchange Offer to comply with all applicable
federal and state securities laws. No securities other than the Exchange Notes
shall be included in the Exchange Offer Registration Statement. The Company and
the Guarantors shall use their best efforts to cause the Exchange Offer to be
Consummated on the earliest practicable date after the Exchange Offer
Registration Statement has become effective, but in no event later than
180 days after the Closing Date (or if such 180th day is not a Business Day, the
next succeeding Business Day).

    (c) The Company and the Guarantors shall indicate in a "Plan of
Distribution" section contained in the Prospectus forming a part of the Exchange
Offer Registration Statement that any Broker-Dealer who holds Initial Notes that
are Transfer Restricted Securities and that were acquired for its own account as
a result of market-making activities or other trading activities (other than
Transfer Restricted Securities acquired directly from the Company), may exchange
such Initial Notes pursuant to the Exchange Offer; however, such Broker-Dealer
may be deemed to be an "underwriter" within the meaning of the Securities Act
and must, therefore, deliver a prospectus meeting the requirements of the
Securities Act in connection with any resales of the Exchange Notes received by
such Broker-Dealer in the Exchange Offer, which prospectus delivery requirement
may be satisfied by the delivery by such Broker-Dealer of the Prospectus
contained in the Exchange Offer Registration Statement. Such "Plan of
Distribution" section shall also contain all other information with respect to
such resales by Broker-Dealers that the Commission may require in order to
permit such resales pursuant thereto, but such "Plan of Distribution" shall not
name any such Broker-Dealer or disclose the amount of Notes held by any such
Broker-Dealer except to the extent required by the Commission as a result of a
change in policy after the date of this Agreement.

                                       4
<Page>
    The Company and the Guarantors shall use their best efforts to keep the
Exchange Offer Registration Statement continuously effective, supplemented and
amended as required by the provisions of Section 6(c) below to the extent
necessary to ensure that it is available for resales of Exchange Notes acquired
by Broker-Dealers for their own accounts as a result of market-making activities
or other trading activities, and to ensure that it conforms with the
requirements of this Agreement, the Securities Act and the policies, rules and
regulations of the Commission as announced from time to time, for a period
ending on the earlier of (i) 180 days from the date on which the Exchange Offer
Registration Statement is declared effective and (ii) the date on which a
Broker-Dealer is no longer required to deliver a prospectus in connection with
market-making or other trading activities.

    The Company and the Guarantors shall provide sufficient copies of the latest
version of such Prospectus to Broker-Dealers promptly upon request at any time
during such 180-day (or shorter as provided in the foregoing sentence) period in
order to facilitate such resales.

SECTION 4.  SHELF REGISTRATION

    (a) SHELF REGISTRATION.  If (i) the Company and the Guarantors are not
required to file an Exchange Offer Registration Statement or to consummate the
Exchange Offer because the Exchange Offer is not permitted by applicable law or
Commission policy (after the procedures set forth in Section 6(a) below have
been complied with), (ii) for any reason the Exchange Offer is not Consummated
within 180 days after the Closing Date (or if such 180th day is not a Business
Day, the next succeeding Business Day), or (iii) with respect to any Holder of
Transfer Restricted Securities, such Holder notifies the Company prior to 20th
day following the Consummation of the Exchange Offer that (A) such Holder is
prohibited by applicable law or Commission policy from participating in the
Exchange Offer, or (B) such Holder may not resell the Exchange Notes acquired by
it in the Exchange Offer to the public without delivering a prospectus and that
the Prospectus contained in the Exchange Offer Registration Statement is not
appropriate or available for such resales by such Holder, or (C) such Holder is
a Broker-Dealer and holds Initial Notes acquired directly from the Company or
one of its affiliates, then, upon such Holder's request, the Company and the
Guarantors shall:

        (x) cause to be filed a shelf registration statement pursuant to
    Rule 415 under the Securities Act, which may be an amendment to the Exchange
    Offer Registration Statement (in either event, the "Shelf Registration
    Statement") as soon as practicable but in any event on or prior to 45 days
    after the date on which the filing obligation arises (or if such 45th day is
    not a Business Day, the next succeeding Business Day) (such date being the
    "Shelf Filing Deadline"), which Shelf Registration Statement shall provide
    for resales of all Transfer Restricted Securities the Holders of which shall
    have provided the information required pursuant to Section 4(b) hereof; and

        (y) use their best efforts to cause such Shelf Registration Statement to
    be declared effective by the Commission on or before the 120th day after
    date on which the filing obligation arises (or if such 120th day is not a
    Business Day, the next succeeding Business Day).

    The Company and the Guarantors shall use their best efforts to keep such
Shelf Registration Statement continuously effective, supplemented and amended as
required by the provisions of Sections 6(b) and (c) hereof to the extent
necessary to ensure that it is available for resales of Notes by the Holders of
Transfer Restricted Securities entitled to the benefit of this
Section 4(a), and to ensure that it conforms with the requirements of this
Agreement, the Securities Act and the policies, rules and regulations of the
Commission as announced from time to time, for a period of at least two years
following the Closing Date (or shorter period that will terminate when all the
Notes covered by such Shelf Registration Statement have been sold pursuant to
such Shelf Registration Statement).

    (b) PROVISION BY HOLDERS OF CERTAIN INFORMATION IN CONNECTION WITH THE SHELF
REGISTRATION STATEMENT.  No Holder of Transfer Restricted Securities may include
any of its Transfer Restricted Securities in any Shelf Registration Statement
pursuant to this Agreement unless and until such Holder furnishes to the Company
in writing, within 20 business days after receipt of a request therefor, such
information as the Company may reasonably request for use in connection with any
Shelf Registration Statement or Prospectus or preliminary Prospectus included
therein. Each Holder as to which any Shelf Registration Statement is being
effected agrees to furnish promptly to the Company all information required to
be disclosed in order to make the information previously furnished to the
Company by such Holder not materially misleading.

                                       5
<Page>
SECTION 5.  SPECIAL INTEREST.  If (i) any of the Registration Statements
required by this Agreement is not filed with the Commission on or prior to the
date specified for such filing in this Agreement, (ii) any of such Registration
Statements has not been declared effective by the Commission on or prior to the
date specified for such effectiveness in this Agreement (the "Effectiveness
Target Date"), (iii) the Exchange Offer has not been Consummated within 30 days
after the Effectiveness Target Date with respect to the Exchange Offer
Registration Statement or (iv) any Registration Statement required by this
Agreement is filed and declared effective but shall thereafter cease to be
effective or fail to be usable for its intended purpose without being succeeded
immediately by a post-effective amendment to such Registration Statement that
cures such failure and that is itself immediately declared effective, unless a
Shelf Registration Statement or its related Prospectus ceases to be effective or
usable solely as a result of the occurrence of a material event with respect to
the Company and/or the Guarantors that would be required by law to be described
in such Shelf Registration Statement or the related Prospectus, provided that
the Company is proceeding promptly and in good faith to amend or supplement such
Shelf Registration Statement or the related Prospectus to describe such event,
(each such event referred to in clauses (i) through (iv), a "Registration
Default"), the Company and the Guarantors hereby agree that the interest rate
borne by the Transfer Restricted Securities shall be increased by 0.25% per
annum during the 90-day period immediately following the occurrence of any
Registration Default and shall increase by an additional 0.25% per annum at the
end of each subsequent 90-day period, but in no event shall such increase exceed
1.00% per annum. Such additional interest to be paid pursuant to a Registration
Default is referred to herein as "Special Interest." Following the cure of all
Registration Defaults relating to any particular Transfer Restricted Securities,
the interest rate borne by the relevant Transfer Restricted Securities will be
reduced to the original interest rate borne by such Transfer Restricted
Securities; provided, however, that, if after any such reduction in interest
rate, a different Registration Default occurs, the interest rate borne by the
relevant Transfer Restricted Securities shall again be increased pursuant to the
foregoing provisions.

    All Special Interest accrued pursuant to this Section 5 shall be paid to the
Holders entitled thereto, in the manner provided for the payment of interest in
the Indenture, on each Interest Payment Date, as more fully set forth in the
Indenture and the Notes.

    All obligations of the Company and the Guarantors set forth in the preceding
paragraph that are outstanding with respect to any Transfer Restricted Security
at the time such security ceases to be a Transfer Restricted Security shall
survive until such time as all such obligations with respect to such Note shall
have been satisfied in full.

SECTION 6.  REGISTRATION PROCEDURES

    (a) EXCHANGE OFFER REGISTRATION STATEMENT.  In connection with the Exchange
Offer, the Company and the Guarantors shall comply with all of the provisions of
Section 6(c) below, shall use their best efforts to effect such exchange to
permit the sale of Transfer Restricted Securities being sold in accordance with
the intended method or methods of distribution thereof, and shall comply with
all of the following provisions:

        (i)  If in the reasonable opinion of counsel to the Company there is a
    question as to whether the Exchange Offer is permitted by applicable law,
    the Company and the Guarantors hereby agree to diligently pursue a favorable
    decision from the Commission allowing the Company and the Guarantors to
    Consummate an Exchange Offer for such Initial Notes.

        (ii) As a condition to its participation in the Exchange Offer pursuant
    to the terms of this Agreement, each Holder of Transfer Restricted
    Securities shall furnish, upon the request of the Company, prior to the
    Consummation thereof, a written representation to the Company (which may be
    contained in the letter of transmittal contemplated by the Exchange Offer
    Registration Statement) to the effect that (A) it is not an affiliate of the
    Company, (B) it is not engaged in, and does not intend to engage in, and has
    no arrangement or understanding with any person to participate in, a
    distribution of the Exchange Notes to be issued in the Exchange Offer and
    (C) it is acquiring the Exchange Notes in its ordinary course of business.
    In addition, all such Holders of Transfer Restricted Securities shall
    otherwise cooperate in the Company's preparations for the Exchange Offer.
    Each Holder hereby acknowledges and agrees that any Broker-Dealer and any
    such Holder using the Exchange Offer to participate in a distribution of the
    securities to be acquired in the Exchange Offer (1) could not under
    Commission policy as in effect on the date of this Agreement rely on the
    position of the

                                       6
<Page>
    Commission enunciated in Morgan Stanley and Co., Inc. (available June 5,
    1991) and Exxon Capital Holdings Corporation (available May 13, 1988), as
    interpreted in the Commission's letter to Shearman & Sterling dated July 2,
    1993, and similar no-action letters (which may include any no-action letter
    obtained pursuant to clause (i) above), and (2) must comply with the
    registration and prospectus delivery requirements of the Securities Act in
    connection with a secondary resale transaction and that such a secondary
    resale transaction should be covered by an effective registration statement
    containing the selling security holder information required by Item 9.B
    or 9.D, as applicable, of Form 20-F or by Item 507 or 508, as applicable, of
    Regulation S-K if the resales are of Exchange Notes obtained by such Holder
    in exchange for Initial Notes acquired by such Holder directly from the
    Company.

    (b) SHELF REGISTRATION STATEMENT.  In connection with the Shelf Registration
Statement, the Company and the Guarantors shall comply with all the provisions
of Section 6(c) below and shall use their best efforts to effect such
registration to permit the sale of the Transfer Restricted Securities being sold
in accordance with the intended method or methods of distribution thereof, and
pursuant thereto the Company and the Guarantors will, in accordance with the
time limitations set forth in Section 4 of this Agreement, prepare and file with
the Commission a Registration Statement relating to the registration on any
appropriate form under the Securities Act, which form shall be available for the
sale of the Transfer Restricted Securities in accordance with the intended
method or methods of distribution thereof.

    (c) GENERAL PROVISIONS.  In connection with any Registration Statement and
any Prospectus required by this Agreement to permit the sale or resale of
Transfer Restricted Securities (including, without limitation, any Registration
Statement and the related Prospectus required to permit resales of Notes by
Broker-Dealers), the Company and the Guarantors shall:

        (i)  use their best efforts to keep such Registration Statement
    continuously effective and provide all requisite financial statements
    (including, if required by the Securities Act or any regulation thereunder,
    financial statements of the Guarantors) for the period specified in
    Section 3 or 4 of this Agreement, as applicable; upon the occurrence of any
    event that would cause (A) any such Registration Statement to contain an
    untrue statement of material fact or omit to state a material fact required
    to be stated therein or necessary to make the statements therein not
    misleading, (B) the Prospectus contained in the Registration Statement to
    contain an untrue statement of a material fact or omit to state a material
    fact required to be stated therein or necessary to make the statements
    therein, in light of the circumstances under which they were made, not
    misleading, or (C) any such Registration Statement or the Prospectus
    contained therein not to be effective or usable for resale of Transfer
    Restricted Securities during the period required by this Agreement, the
    Company and the Guarantors shall file promptly an appropriate amendment to
    such Registration Statement, in the case of clause (A), correcting any such
    misstatement or omission, and, in the case of either
    clause (A), (B) or (C), use their best efforts to cause such amendment to be
    declared effective and such Registration Statement and the related
    Prospectus to become usable for their intended purpose(s) as soon as
    practicable thereafter;

        (ii) prepare and file with the Commission such amendments and
    post-effective amendments to the Registration Statement as may be necessary
    to keep the Registration Statement effective for the applicable period set
    forth in Section 3 or 4 hereof, as applicable, or such shorter period as
    will terminate when all Transfer Restricted Securities covered by such
    Registration Statement have been sold; cause the Prospectus to be
    supplemented by any required Prospectus supplement, and as so supplemented
    to be filed pursuant to Rule 424 under the Securities Act, and to comply
    fully with the applicable provisions of Rules 424 and 430A under the
    Securities Act in a timely manner; and comply with the provisions of the
    Securities Act with respect to the disposition of all securities covered by
    such Registration Statement during the applicable period in accordance with
    the intended method or methods of distribution by the sellers thereof set
    forth in such Registration Statement or supplement to the Prospectus;

        (iii) advise the underwriter(s), if any, and selling Holders promptly
    and, if requested by such Persons, to confirm such advice in writing,
    (A) when the Prospectus or any Prospectus supplement or post-effective
    amendment has been filed, and, with respect to any Registration Statement or
    any post-effective amendment thereto, when the same has become effective,
    (B) of any request by the Commission for amendments to the Registration
    Statement or amendments or supplements to the Prospectus or for additional
    information relating

                                       7
<Page>
    thereto, (C) of the issuance by the Commission of any stop order suspending
    the effectiveness of the Registration Statement under the Securities Act or
    of the suspension by any state securities commission of the qualification of
    the Transfer Restricted Securities for offering or sale in any jurisdiction,
    or the initiation of any proceeding for any of the preceding purposes,
    (D) of the existence of any fact or the happening of any event that makes
    any statement of a material fact made in the Registration Statement, the
    Prospectus, any amendment or supplement thereto, or any document
    incorporated by reference therein untrue, or that requires the making of any
    additions to or changes in (1) the Registration Statement in order to
    correct an omission of a material fact necessary to make the statements
    therein not misleading, or (2) the Prospectus in order to correct an
    omission of a material fact necessary to make the statements therein, in
    light of the circumstances under which they were made, not misleading. If at
    any time the Commission shall issue any stop order suspending the
    effectiveness of the Registration Statement, or any state securities
    commission or other regulatory authority shall issue an order suspending the
    qualification or exemption from qualification of the Transfer Restricted
    Securities under state securities or Blue Sky laws, the Company and the
    Guarantors shall use their reasonable best efforts to obtain the withdrawal
    or lifting of such order at the earliest possible time;

        (iv) furnish without charge to each of the Initial Purchasers, each
    selling Holder named in any Registration Statement, and each of the
    underwriter(s), if any, before filing with the Commission, copies of any
    Registration Statement or any Prospectus included therein or any amendments
    or supplements to any such Registration Statement or Prospectus (including
    all documents incorporated by reference after the initial filing of such
    Registration Statement), which documents will be subject to the review of
    such Holders and underwriter(s) in connection with such sale, if any, for a
    period of at least five business days, and the Company and any Guarantors
    will not file any such Registration Statement or Prospectus or any amendment
    or supplement to any such Registration Statement or Prospectus (including
    all such documents incorporated by reference) to which an Initial Purchaser
    of Transfer Restricted Securities covered by such Registration Statement or
    the underwriter(s), if any, shall reasonably object in writing within five
    business days after the receipt thereof (such objection to be deemed timely
    made upon confirmation of telecopy transmission within such period).

        (v) promptly prior to the filing of any document that is to be
    incorporated by reference into a Registration Statement or Prospectus,
    provide copies of such document to the Initial Purchasers, each selling
    Holder named in any Registration Statement, and to the underwriter(s), if
    any, make the representatives of the Company and the Guarantors available
    for discussion of such document and other customary due diligence matters,
    and include such information in such document prior to the filing thereof as
    such selling Holders or underwriter(s), if any, reasonably may request;

        (vi) make available at reasonable times for inspection by the Initial
    Purchasers, any managing underwriter participating in any disposition
    pursuant to such Registration Statement and any attorney or accountant
    retained by such Initial Purchasers or any of the underwriter(s), all
    financial and other records, pertinent corporate documents and properties of
    the Company and the Guarantors as is customary for similar due diligence
    examinations and cause the Company's and the Guarantors' officers, directors
    and employees to supply all information reasonably requested by any such
    Holder, underwriter, attorney or accountant in connection with such
    Registration Statement subsequent to the filing thereof and prior to its
    effectiveness; PROVIDED that all information and documents supplied by the
    Company shall be kept confidential by the receiving parties unless
    disclosure is required by law or regulation, or by any regulatory authority,
    stock exchange, court or administrative order;

        (vii) if requested by any selling Holders or the underwriter(s), if any,
    promptly incorporate in any Registration Statement or Prospectus, pursuant
    to a supplement or post-effective amendment if necessary, such information
    as such selling Holders and underwriter(s), if any, may reasonably request
    to have included therein, including, without limitation, information
    relating to the "Plan of Distribution" of the Transfer Restricted
    Securities, information with respect to the principal amount of Transfer
    Restricted Securities being sold to such underwriter(s), the purchase price
    being paid therefor and any other terms of the offering of the Transfer
    Restricted Securities to be sold in such offering; and make all required
    filings of such Prospectus supplement or post-effective amendment as soon as
    practicable after the Company is notified of the matters to be incorporated
    in such Prospectus supplement or post-effective amendment;

                                       8
<Page>
        (viii) cause the Transfer Restricted Securities covered by the
    Registration Statement to be rated with the appropriate rating agencies, if
    so requested by the Holders of a majority in aggregate principal amount of
    Notes covered thereby or the underwriter(s), if any;

        (ix) furnish to each selling Holder and each of the underwriter(s), if
    any, without charge, at least one copy of the Registration Statement, as
    first filed with the Commission, and of each amendment thereto, including
    financial statements and schedules, all documents incorporated by reference
    therein and all exhibits (including exhibits incorporated therein by
    reference);

        (x) deliver to each selling Holder and each of the underwriter(s), if
    any, without charge, as many copies of the Prospectus (including each
    preliminary prospectus) and any amendment or supplement thereto as such
    Persons reasonably may request; the Company and the Guarantors hereby
    consent, subject to the provisions of this Agreement, to the use of the
    Prospectus and any amendment or supplement thereto by each of the selling
    Holders and each of the underwriter(s), if any, in connection with the
    offering and the sale of the Transfer Restricted Securities covered by the
    Prospectus or any amendment or supplement thereto;

        (xi) enter into such agreements (including an underwriting agreement)
    and make such representations and warranties in form, substance and scope as
    are customarily made by issuers to underwriters, and take all such other
    actions in connection therewith in order to expedite or facilitate the
    disposition of the Transfer Restricted Securities pursuant to any
    Registration Statement contemplated by this Agreement, all to such extent as
    may be reasonably requested by any Initial Purchaser or by any Holder of
    Transfer Restricted Securities or underwriter in connection with any sale or
    resale pursuant to any Registration Statement contemplated by this
    Agreement; and whether or not an underwriting agreement is entered into and
    whether or not the registration is an Underwritten Registration, the Company
    and the Guarantors shall, with respect to any Shelf Registration Statement:

           (A) furnish to each Initial Purchaser, each selling Holder and each
       underwriter, if any, in such substance and scope as they may request and
       as are customarily made by issuers to underwriters in primary
       underwritten offerings, upon the effectiveness of the Shelf Registration
       Statement:

               (1) a certificate, dated the date of Consummation of the Exchange
           Offer or the date of effectiveness of the Shelf Registration
           Statement, as the case may be, signed by (y) the President or any
           Vice President and (z) a principal financial or accounting officer of
           each of the Company and the Guarantors, confirming, as of the date
           thereof, the matters set forth in paragraphs (i), (ii) and (iii) of
           Section 5 (e) of the Purchase Agreement and such other matters as
           such parties may reasonably request;

               (2) an opinion, dated the date of Consummation of the Exchange
           Offer or the date of effectiveness of the Shelf Registration
           Statement, as the case may be, of counsel for the Company and the
           Guarantors, covering the matters set forth in paragraph (c) of
           Section 5 of the Purchase Agreement and such other matters as such
           parties may reasonably request, and in any event including a
           statement to the effect that such counsel has participated in
           conferences with officers and other representatives of the Company
           and the Guarantors, representatives of the independent public
           accountants for the Company and the Guarantors, the Initial
           Purchasers' representatives and the Initial Purchasers' counsel in
           connection with the preparation of such Registration Statement and
           the related Prospectus and have considered the matters required to be
           stated therein and the statements contained therein, although such
           counsel has not independently verified the accuracy, completeness or
           fairness of such statements; and that such counsel advises that, on
           the basis of the foregoing (relying as to materiality to a large
           extent upon facts provided to such counsel by officers and other
           representatives of the Company and the Guarantors and without
           independent check or verification), no facts came to such counsel's
           attention that caused such counsel to believe that the applicable
           Registration Statement, at the time such Registration Statement or
           any post-effective amendment thereto became effective, and, in the
           case of the Exchange Offer Registration Statement, as of the date of
           Consummation, contained an untrue statement of a material fact or
           omitted to state a material fact required to be stated therein or
           necessary to make the statements therein not misleading, or that the
           Prospectus contained in such Registration Statement as of its date
           and, in the case of the opinion dated the date of Consummation of the
           Exchange Offer, as of the date of Consummation, contained

                                       9
<Page>
           an untrue statement of a material fact or omitted to state a material
           fact necessary in order to make the statements therein, in light of
           the circumstances under which they were made, not misleading. Without
           limiting the foregoing, such counsel may state further that such
           counsel assumes no responsibility for, and has not independently
           verified, the accuracy, completeness or fairness of the financial
           statements, notes and schedules and other financial data included in
           any Registration Statement contemplated by this Agreement or the
           related Prospectus; and

               (3) a customary comfort letter, dated as of the date of
           Consummation of the Exchange Offer or the date of effectiveness of
           the Shelf Registration Statement, as the case may be, from the
           Company's independent accountants, in the customary form and covering
           matters of the type customarily covered in comfort letters to
           underwriters in connection with primary underwritten offerings, and
           affirming the matters set forth in the comfort letters delivered
           pursuant to Section 5(a) of the Purchase Agreement, without
           exception;

           (B) set forth in full or incorporate by reference in the underwriting
       agreement, if any, the indemnification provisions and procedures of
       Section 8 hereof with respect to all parties to be indemnified pursuant
       to said Section; and

           (C) deliver such other documents and certificates as may be
       reasonably requested by such parties to evidence compliance with
       clause (A) above and with any customary conditions contained in the
       underwriting agreement or other agreement entered into by the Company or
       the Guarantors pursuant to this clause (xi), if any.

    If at any time the representations and warranties of the Company and the
Guarantors contemplated in clause (A)(1) above cease to be true and correct, the
Company or the Guarantors shall so advise the Initial Purchasers and the
underwriter(s), if any, and each selling Holder promptly and, if requested by
such Persons, shall confirm such advice in writing;

        (xii) prior to any public offering of Transfer Restricted Securities,
    cooperate with the selling Holders, the underwriter(s), if any, and their
    respective counsel in connection with the registration and qualification of
    the Transfer Restricted Securities under the securities or Blue Sky laws of
    such jurisdictions in the United States as the selling Holders or
    underwriter(s) may request and do any and all other acts or things necessary
    or advisable to enable the disposition in such jurisdictions of the Transfer
    Restricted Securities covered by the Registration Statement; PROVIDED,
    HOWEVER, that neither the Company nor any Guarantor shall be required to
    register or qualify as a foreign corporation where it is not then so
    qualified or to take any action that would subject it to the service of
    process in suits or to taxation, other than as to matters and transactions
    relating to the Registration Statement, in any jurisdiction where it is not
    then so subject;

        (xiii) shall issue, upon the request of any Holder of Initial Notes
    covered by the Shelf Registration Statement, or if the Exchange Offer is to
    be consummated, Exchange Notes, having an aggregate principal amount equal
    to the aggregate principal amount of Initial Notes surrendered to the
    Company by such Holder in exchange therefor or being sold by such Holder;
    such Exchange Notes to be registered in the name of such Holder or in the
    name of the purchaser(s) of such Notes, as the case may be; in return, the
    Initial Notes held by such Holder shall be surrendered to the Company for
    cancellation;

        (xiv) cooperate with the selling Holders and the underwriter(s), if any,
    to facilitate the timely preparation and delivery of certificates
    representing Transfer Restricted Securities to be sold and not bearing any
    restrictive legends; and enable such Transfer Restricted Securities to be in
    such denominations and registered in such names as the Holders or the
    underwriter(s), if any, may request at least two business days prior to any
    sale of Transfer Restricted Securities made by such underwriter(s);

        (xv) if any fact or event contemplated by clause (c)(iii)(D) above shall
    exist or have occurred, prepare a supplement or post-effective amendment to
    the Registration Statement or related Prospectus or any document
    incorporated therein by reference or file any other required document so
    that, as thereafter delivered to the purchasers of Transfer Restricted
    Securities, the Prospectus will not contain an untrue statement of a
    material fact or omit to state any material fact necessary to make the
    statements therein, in light of the circumstances under which they were
    made, not misleading;

                                       10
<Page>
        (xvi) provide a CUSIP number for all Transfer Restricted Securities not
    later than the effective date of the Registration Statement and provide the
    Trustee under the Indenture with printed certificates for the Transfer
    Restricted Securities which are in a form eligible for deposit with the
    Depository Trust Company;

        (xvii) cooperate and assist in any filings required to be made with the
    NASD and in the performance of any due diligence investigation by any
    underwriter (including any "qualified independent underwriter") that is
    required to be retained in accordance with the rules and regulations of the
    NASD, and use their reasonable best efforts to cause such Registration
    Statement to be approved by such governmental agencies or authorities as may
    be necessary to enable the Holders selling Transfer Restricted Securities to
    consummate the disposition of such Transfer Restricted Securities;

        (xviii) otherwise use their best efforts to comply with all applicable
    rules and regulations of the Commission, and make generally available to its
    security holders a consolidated earnings statement of the Company meeting
    the requirements of Rule 158 (which need not be audited) for the
    twelve-month period, no later than 45 days, or 90 days in the case that such
    period is a fiscal year, (A) commencing at the end of any fiscal quarter in
    which Transfer Restricted Securities are sold to underwriters in a firm or
    best efforts Underwritten Offering or (B) if not sold to underwriters in
    such an offering, beginning with the first month of the Company's first
    fiscal quarter commencing after the effective date of the Registration
    Statement;

        (xix) cause all Transfer Restricted Securities covered by the
    Registration Statement to be listed on each securities exchange on which
    similar securities issued by the Company are then listed if requested by the
    Holders of a majority in aggregate principal amount of Initial Notes or the
    managing underwriter(s), if any; and

        (xx) provide promptly to each Holder upon request each document filed
    with the Commission pursuant to the requirements of Section 13 and
    Section 15 of the Exchange Act.

    Each Holder agrees by acquisition of a Transfer Restricted Security that,
upon receipt of any notice from the Company of the existence of any fact of the
kind described in Section 6(c)(iii)(D) hereof, such Holder will forthwith
discontinue disposition of Transfer Restricted Securities pursuant to the
applicable Registration Statement until such Holder's receipt of the copies of
the supplemented or amended Prospectus contemplated by
Section 6(c)(xv) hereof, or until it is advised in writing (the "Advice") by the
Company that the use of the Prospectus may be resumed, and has received copies
of any additional or supplemental filings that are incorporated by reference in
the Prospectus. If so directed by the Company, each Holder will deliver to the
Company (at the Company's expense) all copies, other than permanent file copies
then in such Holder's possession, of the Prospectus covering such Transfer
Restricted Securities that was current at the time of receipt of such notice. In
the event the Company shall give any such notice, the time period regarding the
effectiveness of such Registration Statement set forth in Section 3 or 4 hereof,
as applicable, shall be extended by the number of days during the period from
and including the date of the giving of such notice pursuant to
Section 6(c)(iii)(D) hereof to and including the date when each selling Holder
covered by such Registration Statement shall have received the copies of the
supplemented or amended Prospectus contemplated by Section 6(c)(xv) hereof or
shall have received the Advice; however, no such extension shall be taken into
account in determining whether Special Interest is due pursuant to Section 5
hereof or the amount of such Special Interest, it being agreed that the
Company's option to suspend use of a Registration Statement pursuant to this
paragraph shall be treated as a Registration Default for purposes of Section 5.

SECTION 7.  REGISTRATION EXPENSES.

    (a) All expenses incident to the Company's or the Guarantors' performance of
or compliance with this Agreement will be borne by the Company or the
Guarantors, regardless of whether a Registration Statement becomes effective,
including without limitation: (i) all registration and filing fees and expenses
(including filings made by any Initial Purchaser or Holder with the NASD (and,
if applicable, the fees and expenses of any "qualified independent underwriter"
and its counsel that may be required by the rules and regulations of the NASD));
(ii) all fees and expenses of compliance with federal securities and state Blue
Sky or securities laws; (iii) all expenses of printing (including printing
certificates for the Exchange Notes to be issued in the Exchange Offer and
printing of Prospectuses), messenger and delivery services and telephone;
(iv) all fees and disbursements of counsel for the Company, the Guarantors and,
subject to Section 7(b) below, the Holders of Transfer Restricted

                                       11
<Page>
Securities; (v) all application and filing fees in connection with listing the
Exchange Notes on a national securities exchange or automated quotation system
pursuant to the requirements thereof; and (vi) all fees and disbursements of
independent certified public accountants of the Company and the Guarantors
(including the expenses of any special audit and comfort letters required by or
incident to such performance).

    The Company and the Guarantors will, in any event, bear their internal
expenses (including, without limitation, all salaries and expenses of its
officers and employees performing legal or accounting duties), the expenses of
any annual audit and the fees and expenses of any Person, including special
experts, retained by the Company or the Guarantors.

    (b) In connection with any Registration Statement required by this Agreement
(including, without limitation, the Exchange Offer Registration Statement and
the Shelf Registration Statement), the Company and the Guarantors, jointly and
severally, will reimburse the Initial Purchasers and the Holders of Transfer
Restricted Securities being tendered in the Exchange Offer and/or resold
pursuant to the "Plan of Distribution" contained in the Exchange Offer
Registration Statement or registered pursuant to the Shelf Registration
Statement, as applicable, for the reasonable fees and disbursements of not more
than one counsel, who shall be Shearman & Sterling LLP or such other counsel as
may be chosen by the Holders of a majority in principal amount of the Transfer
Restricted Securities for whose benefit such Registration Statement is being
prepared.

SECTION 8.  INDEMNIFICATION.

    (a) The Company agrees and the Guarantors, jointly and severally, agree to
indemnify and hold harmless (i) each Holder and (ii) each Person, if any, who
controls (within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act) any Holder (any of the persons referred to in this
clause (ii) being hereinafter referred to as a "controlling person") and
(iii) the respective officers, directors, partners, employees, representatives
and agents of any Holder or any controlling person (any person referred to in
clause (i), (ii) or (iii) may hereinafter be referred to as an "Indemnified
Holder"), to the fullest extent lawful, from and against any and all losses,
claims, damages, liabilities, judgments, actions and expenses (including without
limitation and as incurred, reimbursement of all reasonable costs of
investigating, preparing, pursuing, settling, compromising, paying or defending
any claim or action, or any investigation or proceeding by any governmental
agency or body, commenced or threatened, including the reasonable fees and
expenses of counsel to any Indemnified Holder), joint or several, directly or
indirectly caused by, related to, based upon, arising out of or in connection
with (A) any untrue statement or alleged untrue statement of a material fact
contained in any Registration Statement (or any amendment or supplement
thereto), or any omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not
misleading or (B) any untrue statement or alleged untrue statement of a material
fact contained in any Prospectus (or any amendment or supplement thereto), or
any omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, except (i) insofar as
such losses, claims, damages, liabilities or expenses are caused by an untrue
statement or omission or alleged untrue statement or omission that is made in
reliance upon and in conformity with information relating to any of the Holders
furnished in writing to the Company by any of the Holders expressly for use
therein and (ii) the Company and the Guarantors shall not be liable in any such
case to the extent that such loss, claim, damage or liability arises out of or
is based upon the use of a Registration Statement after (x) a stop order has
been issued by the Commission in respect of a Registration Statement or any
proceedings for such purposes have been initiated or (y) a Registration
Statement has been suspended, so long as in the case of (x) and (y), the Holders
shall have received prior notice of such action from the Company in accordance
with this Agreement. This indemnity agreement shall be in addition to any
liability which the Company and the Guarantors may otherwise have.

    In case any action or proceeding (including any governmental or regulatory
investigation or proceeding) shall be brought or asserted against any of the
Indemnified Holders with respect to which indemnity may be sought against the
Company or the Guarantors, such Indemnified Holder (or the Indemnified Holder
controlled by such controlling person) shall promptly notify the Company and the
Guarantors in writing (PROVIDED, that the failure to give such notice shall not
relieve the Company or the Guarantors of their respective obligations pursuant
to this Agreement). Such Indemnified Holder shall have the right to employ its
own counsel in any such action and the fees and expenses of such counsel shall
be paid, as incurred, by the Company and the Guarantors (regardless of whether
it is ultimately determined that an Indemnified Holder is not entitled to
indemnification hereunder). The Company and the Guarantors shall not, in
connection with any one such action or proceeding or separate but

                                       12
<Page>
substantially similar or related actions or proceedings in the same jurisdiction
arising out of the same general allegations or circumstances, be liable for the
reasonable fees and expenses of more than one separate firm of attorneys
(in addition to any local counsel) at any time for such Indemnified Holders,
which firm shall be designated by the Holders. The Company and the Guarantors
shall be liable for any settlement of any such action or proceeding effected
with the Company's and each Guarantor's prior written consent, which consent
shall not be withheld unreasonably, and each of the Company and the Guarantors
agrees to indemnify and hold harmless any Indemnified Holder from and against
any loss, claim, damage, liability or expense by reason of any settlement of any
action effected with the written consent of the Company. The Company and the
Guarantors shall not, without the prior written consent of each Indemnified
Holder, settle or compromise or consent to the entry of judgment in or otherwise
seek to terminate any pending or threatened action, claim, litigation or
proceeding in respect of which indemnification or contribution may be sought
hereunder (whether or not any Indemnified Holder is a party thereto), unless
such settlement, compromise, consent or termination includes an unconditional
release of each Indemnified Holder from all liability arising out of such
action, claim, litigation or proceeding.

    (b) Each Holder of Transfer Restricted Securities agrees, severally and not
jointly, to indemnify and hold harmless the Company and the Guarantors and their
respective directors, officers of the Company who sign a Registration Statement,
and any person controlling (within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act) the Company, the Guarantors and the
respective officers, directors, partners, employees, representatives and agents
of each such person, to the same extent as the foregoing indemnity from the
Company and the Guarantors to each of the Indemnified Holders, but only with
respect to claims and actions based on information furnished in writing by such
Holder expressly for use in any Registration Statement. In case any action or
proceeding shall be brought against the Company, the Guarantors or their
directors or officers or any such controlling person in respect of which
indemnity may be sought against a Holder of Transfer Restricted Securities, such
Holder shall have the rights and duties given the Company and/or the Guarantors
and the Company, the Guarantors or their directors or officers or such
controlling person shall have the rights and duties given to each Holder by the
preceding paragraph.

    (c) If the indemnification provided for in this Section 8 is unavailable to
an indemnified party under Section 8(a) or Section 8(b) hereof (other than by
reason of exceptions provided in those Sections) in respect of any losses,
claims, damages, liabilities, judgments, actions or expenses referred to
therein, then each applicable indemnifying party, in lieu of indemnifying such
indemnified party, shall contribute to the amount paid or payable by such
indemnified party as a result of such losses, claims, damages, liabilities or
expenses in such proportion as is appropriate to reflect the relative benefits
received by the Company and the Guarantors, on the one hand, and the Holders, on
the other hand, from the Initial Placement (which in the case of the Company and
the Guarantors shall be deemed to be equal to the total gross proceeds from the
Initial Placement as set forth on the cover page of the Offering Memorandum),
the amount of Special Interest which did not become payable as a result of the
filing of the Registration Statement resulting in such losses, claims, damages,
liabilities, judgments actions or expenses, and such Registration Statement, or
if such allocation is not permitted by applicable law, the relative fault of the
Company and the Guarantors on the one hand, and of the Indemnified Holder, on
the other hand, in connection with the statements or omissions which resulted in
such losses, claims, damages, liabilities or expenses, as well as any other
relevant equitable considerations. The relative fault of the Company on the one
hand and of the Indemnified Holder on the other shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company or by the Indemnified Holder and
the parties' relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission. The amount paid or payable by
a party as a result of the losses, claims, damages, liabilities and expenses
referred to above shall be deemed to include, subject to the limitations set
forth in the second paragraph of Section 8(a), any legal or other fees or
expenses reasonably incurred by such party in connection with investigating or
defending any action or claim.

    The Company, the Guarantors and each Holder of Transfer Restricted
Securities agree that it would not be just and equitable if contribution
pursuant to this Section 8(c) were determined by pro rata allocation (even if
the Holders were treated as one entity for such purpose) or by any other method
of allocation which does not take account of the equitable considerations
referred to in the immediately preceding paragraph. The amount paid or payable
by an indemnified party as a result of the losses, claims, damages, liabilities
or expenses referred to in the

                                       13
<Page>
immediately preceding paragraph shall be deemed to include, subject to the
limitations set forth above, any legal or other expenses reasonably incurred by
such indemnified party in connection with investigating or defending any such
action or claim. Notwithstanding the provisions of this Section 8, none of the
Holders (and its related Indemnified Holders) shall be required to contribute,
in the aggregate, any amount in excess of the amount by which the total discount
received by such Holder with respect to the Initial Notes exceeds the amount of
any damages which such Holder has otherwise been required to pay by reason of
such untrue or alleged untrue statement or omission or alleged omission. No
person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any
person who was not guilty of such fraudulent misrepresentation. The Holders'
obligations to contribute pursuant to this Section 8(c) are several in
proportion to the respective principal amount of Initial Notes held by each of
the Holders hereunder and not joint.

SECTION 9.  RULE 144A.  The Company and the Guarantors each hereby agrees with
each Holder, for so long as any Transfer Restricted Securities remain
outstanding, to make available to any Holder or beneficial owner of Transfer
Restricted Securities in connection with any sale thereof and any prospective
purchaser of such Transfer Restricted Securities from such Holder or beneficial
owner, the information required by Rule 144A(d)(4) under the Securities Act in
order to permit resales of such Transfer Restricted Securities pursuant to
Rule 144A.

SECTION 10.  PARTICIPATION IN UNDERWRITTEN REGISTRATIONS.  No Holder may
participate in any Underwritten Registration hereunder unless such Holder
(a) agrees to sell such Holder's Transfer Restricted Securities on the basis
provided in any underwriting arrangements approved by the Persons entitled
hereunder to approve such arrangements and (b) completes and executes all
reasonable questionnaires, powers of attorney, indemnities, underwriting
agreements, lock-up letters and other documents required under the terms of such
underwriting arrangements.

SECTION 11.  SELECTION OF UNDERWRITERS.  The Holders of Transfer Restricted
Securities covered by the Shelf Registration Statement who desire to do so may
sell such Transfer Restricted Securities in an Underwritten Offering. In any
such Underwritten Offering, the investment banker or investment bankers and
manager or managers that will administer the offering will be selected by the
Holders of a majority in aggregate principal amount of the Transfer Restricted
Securities included in such offering; provided, that such investment bankers and
managers must be reasonably satisfactory to the Company.

SECTION 12.  MISCELLANEOUS.

    (a) REMEDIES.  The Company and the Guarantors each hereby agrees that
monetary damages would not be adequate compensation for any loss incurred by
reason of a breach by it of the provisions of this Agreement and hereby agree to
waive the defense in any action for specific performance that a remedy at law
would be adequate.

    (b) NO INCONSISTENT AGREEMENTS.  The Company will not, and will cause the
Guarantors not to, on or after the date of this Agreement enter into any
agreement with respect to its securities that is inconsistent with the rights
granted to the Holders in this Agreement or otherwise conflicts with the
provisions hereof. Neither the Company nor any Guarantor has entered into any
agreement granting any registration rights with respect to its securities to any
Person. The rights granted to the Holders hereunder do not in any way conflict
with and are not inconsistent with the rights granted to the holders of the
Company's securities under any agreement in effect on the date hereof.

    (c) ADJUSTMENTS AFFECTING THE NOTES.  The Company and the Guarantors will
not take any action, or permit any change to occur, with respect to the Notes
that would materially and adversely affect the ability of the Holders to
Consummate any Exchange Offer.

    (d) AMENDMENTS AND WAIVERS.  The provisions of this Agreement may not be
amended, modified or supplemented, and waivers or consents to or departures from
the provisions hereof may not be given unless the Company has obtained the
written consent of Holders of a majority of the outstanding principal amount of
Transfer Restricted Securities. Notwithstanding the foregoing, a waiver or
consent to departure from the provisions hereof that relates exclusively to the
rights of Holders whose securities are being tendered pursuant to the Exchange
Offer and that does not affect directly or indirectly the rights of other
Holders whose securities are not being tendered pursuant to such Exchange Offer
may be given by the Holders of a majority of the outstanding principal amount of
Transfer Restricted Securities being tendered or registered; provided that, with
respect to any matter that directly or indirectly adversely affects the rights
of any Initial Purchaser hereunder, the Company shall obtain the written consent
of each such Initial Purchaser with respect to which such amendment,
qualification, supplement, waiver, consent or departure is to be effective.

                                       14
<Page>
    (e) NOTICES.  All notices and other communications provided for or permitted
hereunder shall be made in writing by hand-delivery, first-class mail
(registered or certified, return receipt requested), facsimile, or air courier
guaranteeing overnight delivery:

        (i)  if to a Holder, at the address set forth on the records of the
    Registrar under the Indenture unless a more current address has been
    provided to the Company by such Holder, with a copy to the Registrar under
    the Indenture;

        (ii) if to the Company and the Guarantors:

           Videotron Ltee

           300 Viger Avenue East
           Montreal, Quebec H2X 3W4
           Canada

           Facsimile: (514) 985-8834
           Attention: Frederic Despars

           With a copy to:

           Ogilvy Renault LLP
           1981 McGill College Avenue
           Montreal, Quebec H3A 3C1
           Canada

           Facsimile: (514) 847-4747
           Attention: Marc Lacourciere, Esq.

        (iii) if to the Initial Purchasers:

           Banc of America Securities LLC
           9 West 57th Street, 6th Floor
           New York, NY 10019

           Facsimile: (212) 847-6441
           Attention: High Yield Capital Markets

           With a copy to:

           Shearman & Sterling LLP
           199 Bay Street, Commerce Court West
           Suite 4405, P.O. Box 247
           Toronto, Ontario M5L 1E8

           Facsimile: (416) 360-2958
           Attention: Christopher J. Cummings, Esq.

    All such notices and communications shall be deemed to have been duly given:
at the time delivered by hand, if personally delivered; five business days after
being deposited in the mail, postage prepaid, if mailed; when answered back, if
telexed; when receipt acknowledged, if telecopied; and on the next business day,
if timely delivered to an air courier guaranteeing overnight delivery.

    Copies of all such notices, demands or other communications shall be
concurrently delivered by the Person giving the same to the Trustee at the
address specified in the Indenture.

    (f)  SUCCESSORS AND ASSIGNS.  This Agreement shall inure to the benefit of
and be binding upon the successors and assigns of each of the parties, including
without limitation and without the need for an express assignment, subsequent
Holders of Transfer Restricted Securities; PROVIDED, HOWEVER, that this
Agreement shall not inure to the benefit of or be binding upon a successor or
assign of a Holder unless and to the extent such successor or assign acquired
Transfer Restricted Securities from such Holder.

                                       15
<Page>
    (g) COUNTERPARTS.  This Agreement may be executed in any number of
counterparts and by the parties hereto in separate counterparts, each of which
when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same agreement.

    (h) HEADINGS.  The headings in this Agreement are for convenience of
reference only and shall not limit or otherwise affect the meaning hereof.

    (i)  GOVERNING LAW.  THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

    (j)  CONSENT TO JURISDICTION.  The Company and each Guarantor agree that any
legal suit, action or proceeding, arising out of or based upon this Agreement or
the transactions contemplated hereby ("Related Proceedings") may be instituted
in the federal courts of the United States of America located in the City and
County of New York or the courts of the State of New York in each case located
in the City and County of New York (collectively, the "Specified Courts"), and
each party irrevocably submits to the non-exclusive jurisdiction of such courts
in any such suit, action or proceeding. The Company and each Guarantor
irrevocably appoints CT Corporation System, as its agent to receive service of
process or other legal summons for the purposes of any such suit, action or
proceeding that may be instituted in any state or federal court in the City and
County of New York. Service of any process, summons, notice or document upon
such agent, and written notice of said service by mail to such party's address
set forth above shall be effective service of process for any suit, action or
other proceeding brought in any such court. The parties irrevocably and
unconditionally waive, to the fullest extent permitted by applicable law, any
objection to the laying of venue of any suit, action or other proceeding in the
Specified Courts and irrevocably and unconditionally waive and agree, to the
fullest extent permitted by applicable law, not to plead or claim in any such
court that any such suit, action or other proceeding brought in any such court
has been brought in an inconvenient forum.

    (k) WAIVER OF IMMUNITY.  With respect to any Related Proceeding, each party
irrevocably waives, to the fullest extent permitted by applicable law, all
immunity (whether on the basis of sovereignty or otherwise) from jurisdiction,
service of process, attachment (both before and after judgment) and execution to
which it might otherwise be entitled in the Specified Courts, and with respect
to any proceedings instituted in regard to the enforcement of a judgment of the
Specified Courts (a "Related Judgment"), each party waives any such immunity in
the Specified Courts or any other court of competent jurisdiction, and will not
raise or claim or cause to be pleaded any such immunity at or in respect of any
such Related Proceeding or Related Judgment, including, without limitation, any
immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976,
as amended.

    (l)  JUDGMENT CURRENCY.  If for the purposes of obtaining judgment in any
court it is necessary to convert a sum due hereunder into any currency other
than U.S. dollars, the parties hereto agree, to the fullest extent that they may
effectively do so, that the rate of exchange to be used shall be the rate at
which in accordance with normal banking procedures the indemnified party could
purchase U.S. dollars with such other currency in The City of New York on the
business day preceding that on which final judgment is given. The obligations of
the Company and each Guarantor in respect of any sum due from it to any
indemnified party shall, notwithstanding any judgment in any currency other than
U.S. dollars, not be discharged until the first business day, following receipt
by such indemnified party of any sum adjudged to be so due in such other
currency, on which (and only to the extent that) such indemnified party may in
accordance with normal banking procedures purchase U.S. dollars with such other
currency; if the U.S. dollars so purchased are less than the sum originally due
to such indemnified party hereunder, the Company and each Guarantor agrees, as a
separate obligation and notwithstanding any such judgment, to indemnify such
indemnified party against such loss. If the U.S. dollars so purchased are
greater than the sum originally due to such indemnified party hereunder, such
indemnified party agrees to pay the Company and each Guarantor (but without
duplication) an amount equal to the excess of the dollars so purchased over the
sum originally due to such indemnified party hereunder.

    (m) SEVERABILITY.  In the event that any one or more of the provisions
contained herein, or the application thereof in any circumstance, is held
invalid, illegal or unenforceable, the validity, legality and enforceability of
any such provision in every other respect and of the remaining provisions
contained herein shall not be affected or impaired thereby.

                                       16
<Page>
    (n) ENTIRE AGREEMENT.  This Agreement together with the Purchase Agreement,
the Notes and the Indenture is intended by the parties as a final expression of
their agreement and intended to be a complete and exclusive statement of the
agreement and understanding of the parties hereto in respect of the subject
matter contained herein. There are no restrictions, promises, warranties or
undertakings, other than those set forth or referred to herein with respect to
the registration rights granted by the Company with respect to the Transfer
Restricted Securities. This Agreement supersedes all prior agreements and
understandings between the parties with respect to such subject matter.

                                       17
<Page>
    IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first written above.

<Table>
<S>                                                    <C>  <C>
                                                       VIDEOTRON LTEE

                                                       By:  /s/ JACQUES MALLETTE
                                                            ----------------------------------------------
                                                            Name:  Jacques Mallette
                                                            Title:   Executive Vice President

                                                       GROUPE DE DIVERTISSEMENT SUPERCLUB INC.

                                                       By:  /s/ RICHARD SOLY
                                                            ----------------------------------------------
                                                            Name:  Richard Soly
                                                            Title:   President

                                                       LE SUPERCLUB VIDEOTRON LTEE

                                                       By:  /s/ RICHARD SOLY
                                                            ----------------------------------------------
                                                            Name:  Richard Soly
                                                            Title:   President

                                                       SUPERCLUB VIDEOTRON CANADA INC.

                                                       By:  /s/ RICHARD SOLY
                                                            ----------------------------------------------
                                                            Name:  Richard Soly
                                                            Title:   President

                                                       LES PROPRIETES SUPERCLUB INC.

                                                       By:  /s/ RICHARD SOLY
                                                            ----------------------------------------------
                                                            Name:  Richard Soly
                                                            Title:   President

                                                       CF CABLE TV INC.

                                                       By:  /s/ JACQUES MALLETTE
                                                            ----------------------------------------------
                                                            Name:  Jacques Mallette
                                                            Title:   Executive Vice President

                                                       VIDEOTRON (REGIONAL) LTD.

                                                       By:  /s/ JACQUES MALLETTE
                                                            ----------------------------------------------
                                                            Name:  Jacques Mallette
                                                            Title:   Executive Vice President
</Table>

                                       18
<Page>
    The foregoing Registration Rights Agreement is hereby confirmed and accepted
as of the date first above written:

BANC OF AMERICA SECURITIES LLC
CITIGROUP GLOBAL MARKETS INC.
SCOTIA CAPITAL (USA) INC.
HARRIS NESBITT CORP.
RBC CAPITAL MARKETS CORPORATION
TD SECURITIES (USA) LLC
CIBC WORLD MARKETS CORP.
CREDIT SUISSE FIRST BOSTON LLC
NBF SECURITIES (USA) CORP.
HSBC SECURITIES (USA) INC.
DESJARDINS SECURITIES INTERNATIONAL INC.

<Table>
<S>  <C>
By:  BANC OF AMERICA SECURITIES LLC

By:  /s/ DAN KELLY
     -------------------------------------------
     Managing Director
</Table>

    For itself and the several Initial Purchasers

                                       19
<Page>
                                   SCHEDULE A
                               LIST OF GUARANTORS

                    Groupe de divertissement SuperClub inc.
                          Le Superclub Videotron ltee
                        SuperClub Videotron Canada inc.
                         Les Proprietes SuperClub Inc.
                                CF Cable TV Inc.
                           Videotron (Regional) Ltd.

                                       20<PAGE>

                                                                EXHIBIT 10.19.1

           FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (Infigen IP)

     This First Amendment to Exclusive License Agreement (Infigen IP) ("First
Amendment") is made and entered into as of this 25th day of August, 2005 (the
"Amendment Effective Date"), by and between Advanced Cell, Inc. (formerly known
as Advanced Cell Technology, Inc.), a Delaware corporation with offices located
at 381 Plantation Street, Worcester, Massachusetts 01605 ("LICENSOR"), and
Lifeline Cell Technology, LLC (formerly known as PacGen Cellco, LLC), a
California limited liability company with offices located at 157 Surfview Drive,
Pacific Palisades, CA 90272 ("LICENSEE") (LICENSOR and LICENSEE sometimes
hereinafter referred to individually as a "Party" and collectively as the
"Parties").

     WHEREAS, the Parties previously entered into an Exclusive License Agreement
(Infigen IP), dated May 14, 2004 (the "License Agreement"), which grants
LICENSEE defined rights to use certain intellectual property controlled by
LICENSOR; and

     WHEREAS, the Parties also entered into that certain Agreement to Amend
ACT/Cellco License Agreements dated September 7, 2004 (the "Agreement to
Amend"), which contemplates that the Parties will amend the License Agreement in
certain respects; and

     WHEREAS, the Parties have agreed to amend the License Agreement as provided
herein;

     NOW, THEREFORE, in consideration of the premises and terms of this First
Amendment, and in consideration of the payment to LICENSOR by LICENSEE of
$9,375, the receipt of which is hereby acknowledged by LICENSOR, the Parties
agree to amend the License Agreement as follows:

1.   Section 1.2 is deleted in its entirety and replaced with the following:

     1.2  "FIELD" shall mean the research, development, manufacture and selling
          to third parties of human cells for cell therapy in the treatment of
          human (a) diabetes, (b) liver diseases and (c) retinal diseases and
          retinal degenerative diseases; but FIELD shall exclude applications
          involving the use of cells in the treatment of tumors where the
          primary use of the cells is the destruction or reduction of tumors and
          does not involve regeneration of tissue or organ function.

2.   Section 1.3 is deleted in its entirety and replaced with the following:

     1.3  "KNOW-HOW" means all compositions of matter, techniques and data and
          other know-how and technical inventions (whether or not patentable),
          improvements and developments, practices, methods, concepts, trade
          secrets, documents, computer data, computer code, apparatus, clinical
          and regulatory strategies, test data, analytical and quality control
          data, formulation, manufacturing, patent data or descriptions,
          development information, drawings, specifications, designs, plans,
          proposals and technical data and manuals and all other proprietary

                                         1
<Page>

          information that is owned or controlled by LICENSOR as of the
          Effective Date that relates to cloning technology or to any of the
          subject matter described in or claimed by the PATENT RIGHTS and is
          relevant to the FIELD. By way of illustration, but not in limitation,
          KNOW-HOW shall include commercial rights in the FIELD to any existing
          or potential research products, including reagents, developed by
          LICENSOR in the course of its in-house research as more fully
          described in Section 15.3 of this Agreement. An example of this is the
          proprietary culture medium developed by LICENSOR in the course of the
          development of LICENSOR's proprietary ooplasmic transfer technology.

3.   Section 1.9 is amended by deleting the text in Section 1.9 in its entirety
     and replacing it with the following: "Intentionally omitted".

4.   Section 2.5 is deleted in its entirety and replaced with the following:

          LICENSEE acknowledges and agrees that notwithstanding anything to the
          contrary in this Agreement, LICENSOR may: (i) practice the LICENSED
          TECHNOLOGY and develop and manufacture LICENSED PRODUCTS within the
          FIELD for research purposes, provided that LICENSOR may not market or
          sell LICENSED PRODUCTS in the FIELD to third parties in contravention
          of LICENSEE'S exclusive rights hereunder; (ii) distribute or otherwise
          transfer cells or cell lines or other reagents to collaborators for
          research purposes, and commercialize the results of such research
          (other than media and other reagents produced for sale to the
          commercial research market) outside the FIELD in connection with the
          research, development, manufacture or sale of therapeutic products
          that are not in contravention of LICENSEE'S exclusive rights
          hereunder; and (iii) distribute or otherwise transfer cells or cell
          lines to collaborators for the purposes of researching, developing and
          commercializing cell based therapeutics for purposes other than those
          exclusively licensed to LICENSEE hereunder.

          By way of illustration of subparagraph (ii) of Section 2.5 hereof,
          should LICENSOR partner with a biopharmaceutical company in order to
          produce skin cells for human therapeutic use, and in the process of
          basic research, preclinical, or clinical development find it necessary
          or useful to transfer cell lines or other reagents to that partner to
          facilitate the development of such dermatological product, such
          transfer, provided that the transferred material is not sold or
          marketed to such biopharmaceutical company for monetary compensation,
          shall be considered outside of the FIELD.

          LICENSOR may make LICENSED PRODUCTS available to its collaborators. In
          the event LICENSOR requests that LICENSEE deliver to LICENSOR LICENSED
          PRODUCTS in the FIELD for use in connection with the purposes
          described in the above paragraph, LICENSEE shall make such LICENSED
          PRODUCTS available to LICENSOR on commercially reasonable terms.
          LICENSOR may make LICENSED

                                         2
<Page>

          PRODUCTS in the FIELD, whether developed and manufactured by
          LICENSOR or obtained from LICENSEE, available to its collaborators,
          provided that LICENSOR enters into a license with any such
          collaborator that expressly prohibits the collaborator from
          commercializing the LICENSED TECHNOLOGY in the FIELD or using the
          LICENSED PRODUCTS in the FIELD for any purpose other than in
          connection with the collaboration with LICENSOR for the purposes
          described above. LICENSOR shall provide LICENSEE with a copy of any
          such license entered into with a collaborator prior to delivering
          any LICENSED PRODUCTS in the FIELD; PROVIDED, HOWEVER, that LICENSOR
          may redact from such license agreements any financial terms LICENSOR
          considers proprietary or confidential and not relevant to LICENSEE'S
          exclusive rights hereunder, and PROVIDED FURTHER that any such
          licenses provided to LICENSEE shall be considered and treated as
          Confidential Information under Article 10 of this Agreement. Any
          license by LICENSOR to a collaborator hereunder shall specifically
          provide that any intellectual property developed under such
          collaboration shall be treated as if developed by LICENSOR for
          purposes of determining if it is subject to any of the provisions of
          this Agreement.

5.   Section 2.6 is deleted in its entirety.

6.   Section 4.3 is amended in part by deleting the text (including numbers)
     after the words "and the following minimum amounts:" and replacing such
     text with the following:

          (i)     At 12 months, $7,500
          (ii)    At 24 months, $7,500
          (iii)   At 36 months, $6,875
          (iv)    Annually thereafter, $15,000

7.   Section 15.3 is amended by deleting the words "including any rights
     acquired under Section 15.18 hereof,".

8.   Section 15.18 is amended by deleting the text in said Section in its
     entirety and replacing it with the following:

      15.18 To support the grant of rights hereunder with respect to retinal
            disease, LICENSOR shall provide the services of Robert Lanza, M.D.,
            his assistants and the use of such lab space and equipment as they
            may need that LICENSOR can reasonable supply, understanding that Dr.
            Lanza, his assistants are the full-time employees of LICENSOR and
            the equipment will be primarily used for LICENSOR research. Such
            assistance will be for a period of the earlier of one year from the
            date of this Amendment or until:

            (a)   the completion of preliminary animal studies to assess safety
                  and efficacy of applying cells for the treatment of retinitis
                  pigmentosa and/or

                                         3
<Page>

                  macular degeneration (including any contracts or rights
                  already established for initial animal studies);

            (b)   completion and submission of a scientific paper to a
                  peer-reviewed journal co-authored by LICENSOR and LICENSEE
                  scientists presenting animal data and analysis (subject to the
                  pre-approval of both parties prior to publication);

            (c)   completion of consultations with the FDA to assess the
                  suitability of animal data gathered to initiate the paperwork
                  for early stage human clinical trials;

            (d)   initiation of process of filing the paperwork for early stage
                  human trials.

            A committee composed of Michael West, Ph.D., Robert Lanza, M.D. and
            Irina Klimanskaya, Ph.D., as the LICENSOR representatives, and
            Jeffrey Janus and two additional representatives from LICENSEE that
            LICENSEE will promptly identify to LICENSOR in writing (the
            "Committee"), will meet periodically during the six-month period
            commencing on the Amendment Effective Date to discuss completion of
            the above-identified tasks.

            The LICENSEE Committee representatives may consult informally with
            the LICENSOR Committee representatives, both in person and by
            telephone, regarding issues of mutual interest identified by the
            Committee. The Committee shall meet during such six-month period at
            the facilities of LICENSOR or LICENSEE as shall be mutually
            determined; the time and place of such meetings, and the agenda for
            such meetings, shall be determined by mutual agreement. It is
            contemplated by the Parties that the Committee will meet three times
            during the six-month period. Either party may replace its
            representatives at any time, upon written notice and mutual
            agreement of the parties.

            The foregoing notwithstanding, if LICENSOR is unable or unwilling to
            complete the tasks outlined in this Section 15.18 above, LICENSEE
            shall have the right to manage and carry the work forward so long as
            LICENSEE provides funding for the project, in which case any
            intellectual property that is developed under LICENSEE's management
            and funding shall accrue to LICENSEE, and LICENSEE shall be entitled
            to treat as prepayment of future licensing requirements under this
            and other license agreements between LICENSOR and LICENSEE the
            actual costs incurred by LICENSEE in completing subsections (a)
            through (d) above; PROVIDED, HOWEVER, that LICENSEE shall not be
            entitled to treat any such costs as prepayment of future licensing
            requirements under this and other license agreements between
            LICENSOR and LICENSEE if LICENSOR transfers to LICENSEE the
            technological protocols, techniques and training necessary for
            LICENSEE to replicate LICENSOR'S generation of retinal cells from
            stem cells. LICENSEE and LICENSOR agree that the transfer to

                                         4
<Page>

            LICENSEE of the technological protocols, techniques and training
            necessary for LICENSEE to replicate LICENSOR'S generation of retinal
            cells from stem cells shall be complete when LICENSOR provides
            LICENSEE with written copies of such protocols and techniques and
            two weeks of additional lab training at the Worcester facility by
            two qualified technicians within six months after the Amendment
            Effective Date.

9.    The Agreement is amended by replacing all references to the word "Product"
      with the term "Licensed Product".

10.   This First Amendment shall be governed by and construed in accordance with
      the laws of the State of Delaware, without regard to principles of
      conflicts of law thereof, and shall be binding upon and inure to the
      benefit of the Parties and their respective successors and assigns.

11.   The Parties agree that the Agreement to Amend is terminated by mutual
      agreement and that all of its provisions are superseded in their entirety
      by this First Amendment. The License Agreement, as amended hereby,
      contains the entire agreement of the Parties hereto and thereto with
      respect to the matters discussed herein and therein. This First Amendment
      may not be modified except in writing signed by the Parties.

12.   Except to the extent specifically amended hereby, the terms and provisions
      of the License Agreement are hereby ratified and affirmed in all respects
      and continue in full force and effect.

      IN WITNESS WHEREOF, this First Amendment has been executed by duly
authorized representatives of the Parties as of the Amendment Effective Date.

ADVANCED CELL, INC.

By:  /s/ William M. Caldwell, IV
   -----------------------------------------
Printed Name:  William M. Caldwell, IV
Title:         Chief Executive Officer

LIFELINE CELL TECHNOLOGY, LLC

By:  /s/ Kenneth Aldrich
   -----------------------------------------
Printed Name:  Kenneth Aldrich
Title:         Managing Member

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]